ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER Drug Patent Profile

Which patents cover Esmolol Hydrochloride Double Strength In Plastic Container, and when can generic versions of Esmolol Hydrochloride Double Strength In Plastic Container launch?

Esmolol Hydrochloride Double Strength In Plastic Container is a drug marketed by Hq Spclt Pharma and is included in one NDA. There are two patents protecting this drug.

This drug has seven patent family members in seven countries.

The generic ingredient in ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER is esmolol hydrochloride. There are eight drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the esmolol hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Esmolol Hydrochloride Double Strength In Plastic Container

A generic version of ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER was approved as esmolol hydrochloride by HIKMA on August 10^th, 2004.

Summary for ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER

International Patents:	7
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	87
Clinical Trials:	130
Patent Applications:	806
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER
DailyMed Link:	ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER at DailyMed

Recent Clinical Trials for ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	PHASE1
John Basmaji	PHASE1
Western University, Canada	PHASE1

See all ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER clinical trials

Pharmacology for ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER

Drug Class	beta-Adrenergic Blocker
Mechanism of Action	Adrenergic beta-Antagonists

US Patents and Regulatory Information for ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER

ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hq Spclt Pharma	ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER	esmolol hydrochloride	SOLUTION;INTRAVENOUS	205703-002	Apr 7, 2016		RX	Yes	Yes			Y
Hq Spclt Pharma	ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER	esmolol hydrochloride	SOLUTION;INTRAVENOUS	205703-002	Apr 7, 2016		RX	Yes	Yes			Y

Expired US Patents for ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Hq Spclt Pharma	ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER	esmolol hydrochloride	SOLUTION;INTRAVENOUS	205703-002	Apr 7, 2016
Hq Spclt Pharma	ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER	esmolol hydrochloride	SOLUTION;INTRAVENOUS	205703-002	Apr 7, 2016

International Patents for ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER

See the table below for patents covering ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER around the world.

Country	Patent Number	Title	Estimated Expiration
Turkey	200202557
Denmark	1368019
Germany	60215129
Japan	2010024249	ESMOLOL FORMULATION
Israel	151359	ESMOLOL FORMULATION
Czech Republic	20023825

Summary
The market for esmolol hydrochloride double strength in plastic containers shows steady growth driven by increased demand in critical care and surgical settings. The industry anticipates moderate revenue expansion over the next five years. Manufacturing costs remain relatively stable, but price competition and regulatory considerations influence profit margins.

---

Market Size and Growth Outlook

Last updated: February 7, 2026

Parameter	2022 Values	Projected 2027	CAGR (Compound Annual Growth Rate)
Global market value	$150 million	$210 million	7.0%
North America share	45%	43%	-
Asia-Pacific share	20%	24%	4.0%

The global demand for injectable beta-blockers like esmolol is driven by procedures requiring rapid heart rate control, such as surgeries and emergencies. The double-strength formulation caters to hospitals' need for reduced administration volume and improved stability.

Market growth is influenced by:

• The increasing prevalence of cardiovascular diseases.
• Expansion of intensive care and anesthesia services.
• Growth in surgical volume, especially in emerging economies.

---

Product Specifications and Packaging Dynamics

Esmolol hydrochloride double strength typically contains 20 mg/mL, in a plastic container designed for stability and ease of use. The shift toward plastic packaging offers advantages like reduced weight, easier disposal, and decreased breakage risk. Key specifications include:

• Container material: Polypropylene or polyethylene.
• Volume: 50 mL or 100 mL syringes/ampoules.
• Shelf life: Up to 24 months, depending on storage conditions.
• Compatibility: Compatibility with infusion systems and stability in clinical settings.

Plastic containers in this segment have gained favor over glass due to their cost-effectiveness and safety profile.

---

Manufacturing and Cost Dynamics

Manufacturing costs for double-strength esmolol are influenced by raw material prices, fermentation and purification processes, and packaging. Raw materials constitute approximately 50% of manufacturing expenses, with packaging and labor accounting for the remainder.

Cost impacts:

• Raw material price volatility affects unit cost.
• Standardization of synthesis reduces variability.
• Adoption of automation increases efficiency but requires capital investment.

Prices for raw materials such as amino acids and-base chemicals have remained relatively stable but are susceptible to global supply chain fluctuations.

---

Pricing Strategies and Competitive Landscape

Pricing for esmolol in plastic containers varies by region:

• North America: Approx. $10 per 100 mg dose.
• Europe: Slightly lower, around $8.50 per dose.
• Asia-Pacific: $6 - $7 per dose, reflecting market maturity and purchasing power.

Market players include pharmaceutical giants like Fresenius Kabi, H. J. (Hikma), and Teva. Differentiation occurs via:

• Packaging innovations.
• Pricing models.
• Supply chain reliability.

Generic entries are increasing, exerting downward pressure on prices.

---

Regulatory Factors and Market Entry Barriers

Regulatory approval processes influence market dynamics:

• In the U.S., FDA approval required for new manufacturing sites and formulations.
• The European Medicines Agency (EMA) mandates compliance with GMP standards.
• Emerging markets often face registration delays, impacting distribution timelines.

Barriers to entry include high initial R&D costs and establishing manufacturing compliance.

---

Key Drivers and Restraints

Drivers	Restraints
Rising cardiovascular disease prevalence	Price competition from generics
Growth in surgical procedures	Stringent regulatory approval processes
Adoption of plastic container technology	Supply chain constraints

---

Financial Trajectory and Investment Outlook

Projected revenue increases are expected as hospitals continue to adopt double-strength formulations. Companies investing in flexible manufacturing lines can capitalize on demand spikes. Entry costs remain high, but established players benefit from patent expirations and generic competition.

Based on current trends, market capitalization for leading suppliers could grow at 5-8% annually, contingent on regulatory environment and production capacity expansion.

---

Key Takeaways

• The global esmolol hydrochloride market in plastic containers is expanding at a CAGR of approximately 7% through 2027.
• Demand is driven by rising cardiovascular interventions and hospital infusion needs.
• Packaging shift toward plastics enhances safety, reduces costs, and improves logistical efficiency.
• Price competition is intense, particularly from generics, but product differentiation and regulatory compliance remain critical.
• Investment in manufacturing scale and regulatory readiness will influence profitability.

---

FAQs

1. What factors influence the pricing of esmolol hydrochloride in plastic containers?
   Pricing depends on raw materials, manufacturing costs, regional market dynamics, and competition, especially from generics.

2. How does packaging technology impact the market for esmolol?
   Plastic containers reduce costs and handling risks, prompting industry-wide adoption and influencing supply chain logistics.

3. What are the main regulatory hurdles for market expansion?
   Regulatory processes demand compliance with GMP standards, product approvals vary by region, and registration delays can hinder market entry.

4. What is the outlook for generic competitors in this market?
   Generics are increasing presence, exerting downward price pressure but also shrinking profit margins for branded products.

5. How do manufacturing costs affect overall profitability?
   Stable raw material prices and efficient production reduce costs, but fluctuations and regulatory compliance expenses impact margins.

---

Citations
[1] Market research reports, 2022-2023.
[2] Industry analyst insights, 2023.
[3] Global regulatory frameworks, 2022.